| Literature DB >> 35326916 |
Akshaya Srikanth Bhagavathula1, Mohammadjavad Ashrafi Mahabadi2, Wubshet Tesfaye3, Kesavan Rajasekharan Nayar4, Vijay Kumar Chattu5,6,7.
Abstract
In late November 2021, a new SARS-CoV-2 Variant of Concern (VOC) named Omicron (initially named B.1.1.529) was first detected in South Africa. The rapid spread of the SARS-CoV-2 Omicron variant became globally dominant, and the currently available COVID-19 vaccines showed less protection against this variant. This study aimed to investigate healthcare workers' (HCWs) knowledge and perceptions about the novel SARS-CoV-2 Omicron variant. A cross-sectional anonymous electronic survey concerning the SARS-CoV-2 Omicron variant was conducted among HCWs during the second week of January 2022. The survey instrument was distributed through social media among HCWs to explore awareness (2 items), knowledge (10 items), source of information (1 item), and perceptions (10 items). Respondents who answered ≥80% of the items correctly were considered as having good knowledge and perception. A total of 940 of the 1054 HCW participants completed the survey (response rate: 89.1%); they had a mean age of 31.2 ± 11.2 years, most were doctors (45.7%), and most were from Asia (64.3%). All the participants were aware of the SARS-CoV-2 Omicron variant (100%). Only 36.3% attended lectures/discussions about Omicron and used news media to obtain information. Only a quarter of the HCWs demonstrated good knowledge (24.3%, n = 228) and perception (20.6%) about Omicron. However, while significant differences were observed in the knowledge and perception among HCWs, only a small proportion of doctors exhibited good knowledge (13%) and perception (10%) about the Omicron variant. HCWs who had participated in training/discussion related to the Omicron variant were more likely to have higher knowledge and perception scores (odds ratio: 1.80; 95% confidence interval: 1.04-3.11). As the SARS-CoV-2 Omicron variant spreads rapidly across the globe, ongoing educational interventions are warranted to improve knowledge and perceptions of HCWs.Entities:
Keywords: COVID-19; Omicron; SARS-CoV-2; attitude; awareness; health professionals; knowledge; perceptions; prevention; survey
Year: 2022 PMID: 35326916 PMCID: PMC8951382 DOI: 10.3390/healthcare10030438
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Characteristics of study participants (N = 940).
| Variable | Frequency (%) |
|---|---|
| Sex | |
| Male | 539 (57.3) |
| Female | 401 (42.7) |
| Age (mean ± SD) | 31.2 ± 11.2 years |
| 18-29 | 530 (56.4) |
| 30-39 | 194 (20.6) |
| ≥40 | 216 (23) |
| Participant’s Location | |
| Asia | 604 (64.3) |
| Africa | 137 (14.6) |
| Europe | 125 (13.3) |
| South America | 39 (4.1) |
| North America | 28 (3.0) |
| Oceanic | 7 (0.7) |
| Profession | |
| Doctors | 430 (45.7) |
| Medical students | 225 (23.9) |
| Pharmacists | 120 (12.8) |
| Nurses | 60 (6.4) |
| Allied health | 105 (11.2) |
| I Heard of SARS-CoV-2 Omicron | 940 (100) |
| I Attended Lectures/Dissions About Omicron | 341 (36.3) |
| Survey Completion Time (mean ± SD) | 5.9 ± 3.9 min |
SD: standard deviation.
Figure 1Healthcare workers’ sources of reliable information on the SARS-CoV-2 Omicron variant.
Figure 2Healthcare workers correctly identified WHO-designated SARS-CoV-2 Variants of Concern (VOCs) and their countries of origin.
Healthcare professionals’ knowledge and Perceptions about the SARS-CoV-2 Omicron.
| Items Related to the SARS-CoV-2 Omicron Variant | Correct Response (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Knowledge |
|
|
|
|
|
| ||||
| The Omicron variant was first reported to the World health organization from South Africa | 328 (76.3) | 132 (58.7) | 46 (76.7) | 73 (60.8) | 69 (65.7) | 0.002 | <0.001 | 0.001 | 0.010 | <0.001 |
| Skin rash is not a symptom of Omicron | 341 (79.3) | 163 (72.4) | 45 (75) | 83 (77.5) | 73 (69.5) | 0.315 | 0.767 | 0.048 | 0.952 | 0.060 |
| Omicron can be transmited to all age groups | 402 (93.5) | 197 (87.6) | 57 (95) | 112 (93.3) | 91 (86.7) | 0.051 | 0.021 | 0.033 | 0.434 | 0.080 |
| Wearing a face mask, hand hygiene, social distancing, indoor ventilation, avoiding crowded places, and COVID-19 vaccination can protect from Omicron | 403 (93.5) | 208 (92.4) | 57 (95) | 112 (93.3) | 93 (88.6) | 0.693 | 0.991 | 0.458 | 0.443 | 0.590 |
| Taking two doses of COVID-19 vaccination is important | 394 (91.6) | 194 (86.2) | 52 (86.7) | 108 (90.0) | 90 (85.7) | 0.167 | 0.243 | 0.025 | 0.009 | 0.295 |
|
| ||||||||||
| Currently available COVID-19 vaccines offer protection against Omicron | 140 (32.6) | 74 (32.9) | 17 (28.3) | 41 (34.2) | 34 (32.4) | 0.888 | 0.177 | 0.978 | 0.855 | 0.326 |
| A COVID-19 booster dose offers protection against Omicron | 173 (40.2) | 92 (40.9) | 18 (30.0) | 53 (44.2) | 39 (37.1) | 0.331 | 0.149 | 0.606 | 0.269 | 0.906 |
| COVID-19 mutations could alter the response to vaccines, treatment, and transmissibility | 264 (61.4) | 112 (49.8) | 38 (63.3) | 67 (55.8) | 60 (57.1) | 0.044 | 0.516 | 0.030 | 0.244 | 0.954 |
| Both vaccinated and unvaccinated people are vulnerable to Omicron | 388 (90.2) | 196 (87.1) | 56 (93.3) | 104 (86.7) | 89 (84.8) | 0.294 | 0.335 | 0.152 | 0.125 | 0.989 |
| Travel bans cannot limit the global spread of Omicron | 111 (25.8) | 48 (21.3) | 18 (30) | 18 (15) | 26 (24.8) | 0.085 | 0.004 | 0.126 | 0.324 | <0.001 |
| Older people and people with comorbidities should postpone travel | 396 (92.1) | 211 (93.8) | 54 (90) | 109 (90.8) | 95 (90.5) | 0.764 | 0.807 | 0.941 | 0.193 | 0.314 |
| Steroids are not effective against severe Omicron | 200 (46.5) | 114 (50.7) | 33 (55) | 69 (57.5) | 72 (68.6) | <0.001 | 0.009 | 0.002 | 0.413 | 0.678 |
| A COVID-19 rapid antigen test is not reliable to detect the Omicron | 174 (40.5) | 100 (44.4) | 25 (41.7) | 54 (45) | 44 (41.9) | 0.847 | 0.475 | 0.314 | 0.998 | 0.060 |
| Face masks offer protection against all SARS-CoV-2 variants | 370 (86) | 191 (84.9) | 46 (76.7) | 104 (86.7) | 82 (78.1) | 0.122 | 0.501 | 0.192 | 0.419 | 0.125 |
| Countries should accelerate the COVID-19 vaccination program | 405 (94.2) | 206 (91.6) | 54 (90) | 109 (90.8) | 96 (91.4) | 0.516 | 0.472 | 0.080 | 0.381 | 0.179 |
Variance: ANOVA test (p-value): all the comparisons were analyzed using a Mann–Whitney U-test.
ANCOVA test to compare the participants’ knowledge and perception score variations across health specialties.
| Specialty | Frequency | Median (Range) | F | df | ||
|---|---|---|---|---|---|---|
|
| Doctors | 430 | 14 (0–20) | 3.82 | 4 | 0.004 |
| Medical students | 225 | 12 (4–20) | ||||
| Nurses | 60 | 12 (6–20) | ||||
| Pharmacists | 120 | 12 (2–20) | ||||
| Allied Health | 105 | 12 (2–20) | ||||
|
| Doctors | 430 | 13 (5–18) | 0.374 | 4 | 0.827 |
| Medical students | 225 | 12 (6–20) | ||||
| Nurses | 60 | 12 (6–18) | ||||
| Pharmacists | 120 | 12 (6–20) | ||||
| Allied Health | 105 | 12 (4–18) |
Overall knowledge and perception levels across subgroups.
| Subgroup | Knowledge | Perception | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Good | Moderate | Poor | Good | Neutral | Misperceptions | ||||
| Scores | 16–20 | 12–15 | <12 | 16–20 | 12–15 | <12 | |||
| Total | N= 940 | 228 (24.3) | 409 (43.5) | 303 (32.2) | <0.001 | 194 (20.6) | 492 (52.3) | 254 (27) | 0.001 |
| Sex | 0.624 | 0.913 | |||||||
| Male | 132 (14) | 240 (25.5) | 167 (17.8) | 109 (11.6) | 285 (30.3) | 145 (15.4) | |||
| Female | 96 (10.2) | 169 (18) | 136 (14.5) | 85 (9) | 207 (22) | 109 (11.6) | |||
| Age (years) | 0.002 | 0.132 | |||||||
| <30 | 118 (12.6) | 216 (23) | 196 (20.9) | 97 (10.3) | 286 (30.4) | 147 (15.6) | |||
| ≥30 | 110 (11.7) | 193 (20.5) | 107 (11.4) | 97 (10.3) | 206 (21.9) | 107 (11.4) | |||
| Countries | <0.001 | 0.369 | |||||||
| Developing | 178 (18.9) | 312 (33.3) | 266 (28.3) | 43 (4.6) | 98 (10.4) | 43 (4.6) | |||
| Developed | 50 (5.3) | 97 (10.3) | 37 (3.9) | 151 (16.1) | 394 (41.9) | 211 (22.4) | |||
| Profession | 0.001 | 0.496 | |||||||
| Doctors | 121 (12.9) | 203 (21.6) | 106 (11.3) | 94 (10) | 227 (24.1) | 109 (11.6) | |||
| Medical students | 42 (4.5) | 87 (9.3) | 96 (10.2) | 46 (4.9) | 109 (11.6) | 70 (7.4) | |||
| Nurses | 15 (1.6) | 27 (2.9) | 18 (1.9) | 12 (1.3) | 36 (3.8) | 12 (1.3) | |||
| Pharmacists | 27 (2.9) | 50 (5.3) | 43 (4.6) | 18 (1.9) | 68 (7.2) | 32 (3.6) | |||
| Allied health | 23 (2.4) | 42 (4.5) | 40 (4.3) | 24 (2.6) | 52 (5.5) | 29 (3.1) | |||
Factors associated with good knowledge and perception about the SARS-CoV-2 Omicron.
| Odds Ratio (95% Confidence Intervals) | ||||
|---|---|---|---|---|
| Categories | Good Knowledge | Good Perception | Both | |
| Sex | Female | 1 | 1 | 1 |
| Male | 0.93 (0.68–1.27) | 0.89 (0.64–1.24) | 0.85 (0.49–1.47) | |
| Age | Years | 1.07 (0.99–1.02) | 1.01 (1.00–1.03) * | 1.01 (0.99–1.04) |
| Location | Asia | 1 | 1 | 1 |
| Africa | 0.48 (0.26–78) ** | 0.55 (0.31–0.95) * | 0.21 (0.05–0.92) * | |
| Europe | 1.18 (0.76–1.84) | 1.14 (0.70–1.84) | 1.33 (0.66–2.68) | |
| South America | 1.23 (0.53–2.86) | 2.69 (1.21–6.00) * | 1.37 (0.37–5.00) | |
| North America | 0.53 (0.06–4.52) | 2.84 (0.62–12.91) | - | |
| Oceanic | 0.73 (0.33–1.63) | 2.04 (1.00–4.16) * | 0.90 (0.25–3.22) | |
| Profession | Doctors | 1 | 1 | 1 |
| Medical students | 0.67 (0.43–1.04) | 1.15 (0.70–1.76) | 0.85 (0.37–1.94) | |
| Pharmacists | 0.91 (0.48–1.72) | 0.86 (0.43–1.70) | 1.08 (0.40–2.96) | |
| Nurses | 0.85 (0.51–1.42) | 0.72 (0.40–1.30) | 0.59 (0.19–1.81) | |
| Allied health | 0.77 (0.46–1.29) | 1.07 (0.64–1.80) | 0.78 (0.31–1.95) | |
| Engaged in Omicron-related training/discussions | No | 1 | 1 | 1 |
| Yes | 1.72 (1.27–2.38) ** | 0.98 (0.70–1.38) | 1.80 (1.04–3.11) ** | |
Adjusted: age, gender, location, profession, and engaged in training/discussion. * p < 0.05; ** p < 0.01.